Oncotelic Therapeutics, Inc.
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.
On February 28, 2023, Fatih Uckun, MD, Ph. D, Chief Medical Officer (“ CMO ”) of Oncotelic Therapeutics, Inc. (the “ Company ”), notified the Company of his resignation as the Company’s CMO, effective February 28, 2023.
Dr. Seymour Fein MD, Chief Regulatory Officer (“CRO”) of the Company, will be taking over the CMO role.
Extracted from this filing and checked against the source text.
Fatih Uckun resigned as Chief Medical Officer at Oncotelic Therapeutics, Inc..
On February 28, 2023, Fatih Uckun, MD, Ph. D, Chief Medical Officer (“ CMO ”) of Oncotelic Therapeutics, Inc. (the “ Company ”), notified the Company of his resignation as the Company’s CMO, effective February 28, 2023.View on SEC.gov
Seymour Fein was appointed as Chief Medical Officer at Oncotelic Therapeutics, Inc..
Dr. Seymour Fein MD, Chief Regulatory Officer (“CRO”) of the Company, will be taking over the CMO role.View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.